等待开盘 04-02 09:30:00 美东时间
+0.007
+1.11%
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same
04-01 05:34
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Nexgel updates its financial calendar; management hosts a conference call at 4:30 P.M. ET NEXGEL will report financial results for the fourth quarter and full year ended December 31, 2025 after the market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET on March 31, 20
03-25 21:04
NEXGEL, Inc., a leading provider of healthcare, beauty, and OTC products, including hydrogel products, announced it will report its fourth-quarter and full-year 2025 financial results on March 31, 2026, after market close. The company will host a conference call at 4:30 P.M. ET on the same day. The call can be accessed via phone or webcast, with information provided for dial-in numbers and a live webcast link. A replay will be available until Apr...
03-25 13:00
Gainers Azitra (AMEX:AZTR) stock rose 52.6% to $0.27 during Friday's regular s...
03-21 01:06
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 23.3% to $0.16 during Tues...
03-11 05:06
The latest update is out from Celularity ( ($CELU) ). On March 6, 2026, Celular...
03-10 21:35
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million and make the company profitable.
03-10 20:30
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
NEXGEL, Inc. has signed a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., expected to triple NEXGEL’s annual revenue to approximately $35 million and make the company immediately profitable. The transaction includes six established regenerative biomaterial products with existing insurance reimbursement, three new product 510(k) filings planned for 2026-2028, and t...
03-10 12:45